Related Experiment Video
Updated: Aug 6, 2026
07:37
Genetic Engineering of Primary Mouse Intestinal Organoids Using Magnetic Nanoparticle Transduction Viral Vectors for Frozen Sectioning
Published on: May 10, 2019
VitroOrganoSphere (VOS): an automated droplet-engineered organoid sorting platform
Zhangjie Li1,2, Rong Zhao3, Chenyang Zhou1,2
1National Key Laboratory of Advanced Micro and Nano Manufacture Technology, Shanghai Jiao Tong University, Shanghai, 200240, China. xlwang83@sjtu.edu.cn.
Lab on a Chip
|July 20, 2026
Summary
The VitroOrganoSphere (VOS) system automates organoid sorting using droplet technology, improving reproducibility and reducing matrix use for drug screening. This platform enhances organoid growth and drug sensitivity testing for precision medicine applications.
Area of Science:
- Biotechnology
- Cell Biology
- Drug Discovery
Background:
- Organoid technology faces challenges in automation, reproducibility, and high matrix consumption, hindering industrialization and clinical translation.
- Current methods limit efficient, high-throughput organoid analysis and drug screening.
Purpose of the Study:
- To develop an automated droplet-based platform for organoid sorting and dispensing.
- To improve the efficiency, reproducibility, and scalability of organoid handling for drug screening.
Main Methods:
- The VitroOrganoSphere (VOS) system integrates droplet generation, photoelectric detection, fluorescence-based content evaluation, sorting, and automated dispensing.
- Utilizes monodisperse droplets with low Matrigel consumption and real-time quality control for droplet selection.
- Employs size and sample content criteria for rigorous screening of encapsulated organoids.
Main Results:
- Achieved >90% recovery rate and >95% accuracy in organoid sorting and dispensing.
- Demonstrated enhanced organoid viability and growth compared to manual methods.
- Successfully performed drug sensitivity testing on patient-derived tumor organoids, revealing interpatient heterogeneity.
Conclusions:
- The VOS system provides a standardized, automated workflow for organoid-based drug screening.
- This platform supports precision medicine by enabling reliable and efficient analysis of patient-derived organoids.
- The VOS system overcomes limitations of current organoid technologies, paving the way for broader clinical applications.
